NewAmsterdam Pharma Company (NAMS) Stock Forecast & Price Target

Compare

240 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NAMS Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

NewAmsterdam

Pharma Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NAMS Stock 12 Month Forecast

Average Price Target

$48.43

▲(37.94% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for NewAmsterdam Pharma Company in the last 3 months. The average price target is $48.43 with a high forecast of $60.00 and a low forecast of $37.00. The average price target represents a 37.94% change from the last price of $35.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","28":"$28","39":"$39","50":"$50","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,28,39,50,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.61,41.17846153846154,42.746923076923075,44.315384615384616,45.88384615384615,47.45230769230769,49.02076923076923,50.58923076923077,52.15769230769231,53.72615384615385,55.29461538461538,56.863076923076925,58.431538461538466,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.61,40.28846153846154,40.966923076923074,41.645384615384614,42.323846153846155,43.00230769230769,43.68076923076923,44.35923076923077,45.03769230769231,45.716153846153844,46.394615384615385,47.073076923076925,47.75153846153846,{"y":48.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.61,39.40923076923077,39.208461538461535,39.00769230769231,38.80692307692308,38.606153846153845,38.40538461538461,38.20461538461539,38.003846153846155,37.80307692307692,37.60230769230769,37.401538461538465,37.20076923076923,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$48.43

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Condulis

Stifel Nicolaus

$44→$50

Buy

42.41%

Upside

Reiterated

12/16/25

Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Asad Haider

Goldman Sachs

$30→$37

Hold

5.38%

Upside

Reiterated

12/02/25

NewAmsterdam Pharma price target raised to $37 from $30 at Goldman SachsNewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/11/25

Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential

Leonid Timashev

RBC Capital

$44

Buy

25.32%

Upside

Reiterated

11/10/25

RBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Yasmeen Rahimi

Piper Sandler

$37→$60

Buy

70.89%

Upside

Reiterated

11/10/25

Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

Joseph Pantginis

H.C. Wainwright

$48→$52

Buy

48.11%

Upside

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Emergent Biosolutions (NYSE: EBS) and Ginkgo Bioworks Holdings (NYSE: DNA)

Serge Belanger

Needham

$40→$46

Buy

31.02%

Upside

Reiterated

11/05/25

NewAmsterdam Pharma's Promising Developments and EU Approval Prospects Drive Buy Rating

Matt Phipps

William Blair

Buy

―

Reiterated

11/05/25

Positive Outlook for NewAmsterdam Pharma: Strong Q3 Performance and Promising Developments

Geoff Meacham

Citi

$42→$50

Buy

42.41%

Upside

Reiterated

10/20/25

NewAmsterdam Pharma price target raised to $50 from $42 at CitiNewAmsterdam Pharma price target raised to $50 from $42 at Citi

Yanan Zhu

Wells Fargo

$45

Buy

28.17%

Upside

Initiated

08/25/25

NewAmsterdam Pharma initiated with an Overweight at Wells FargoNewAmsterdam Pharma initiated with an Overweight at Wells Fargo

Roanna Ruiz

Leerink Partners

$45→$44

Buy

25.32%

Upside

Reiterated

08/07/25

Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data

George Farmer

Scotiabank

$52

Buy

48.11%

Upside

Reiterated

08/07/25

Scotiabank Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Steven Seedhouse

Cantor Fitzgerald

$42

Buy

19.62%

Upside

Reiterated

07/30/25

Cantor Fitzgerald Remains a Buy on NewAmsterdam Pharma Company (NAMS)

Dennis Ding

Jefferies

$45

Buy

28.17%

Upside

Reiterated

06/11/25

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer's Opportunities

Debjit Chattopadhyay

Guggenheim

$35→$41

Buy

16.78%

Upside

Reiterated

03/03/25

NewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimNewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Condulis

Stifel Nicolaus

$44→$50

Buy

42.41%

Upside

Reiterated

12/16/25

Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Asad Haider

Goldman Sachs

$30→$37

Hold

5.38%

Upside

Reiterated

12/02/25

NewAmsterdam Pharma price target raised to $37 from $30 at Goldman SachsNewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/11/25

Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential

Leonid Timashev

RBC Capital

$44

Buy

25.32%

Upside

Reiterated

11/10/25

RBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Yasmeen Rahimi

Piper Sandler

$37→$60

Buy

70.89%

Upside

Reiterated

11/10/25

Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

Joseph Pantginis

H.C. Wainwright

$48→$52

Buy

48.11%

Upside

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Emergent Biosolutions (NYSE: EBS) and Ginkgo Bioworks Holdings (NYSE: DNA)

Serge Belanger

Needham

$40→$46

Buy

31.02%

Upside

Reiterated

11/05/25

NewAmsterdam Pharma's Promising Developments and EU Approval Prospects Drive Buy Rating

Matt Phipps

William Blair

Buy

―

Reiterated

11/05/25

Positive Outlook for NewAmsterdam Pharma: Strong Q3 Performance and Promising Developments

Geoff Meacham

Citi

$42→$50

Buy

42.41%

Upside

Reiterated

10/20/25

NewAmsterdam Pharma price target raised to $50 from $42 at CitiNewAmsterdam Pharma price target raised to $50 from $42 at Citi

Yanan Zhu

Wells Fargo

$45

Buy

28.17%

Upside

Initiated

08/25/25

NewAmsterdam Pharma initiated with an Overweight at Wells FargoNewAmsterdam Pharma initiated with an Overweight at Wells Fargo

Roanna Ruiz

Leerink Partners

$45→$44

Buy

25.32%

Upside

Reiterated

08/07/25

Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data

George Farmer

Scotiabank

$52

Buy

48.11%

Upside

Reiterated

08/07/25

Scotiabank Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Steven Seedhouse

Cantor Fitzgerald

$42

Buy

19.62%

Upside

Reiterated

07/30/25

Cantor Fitzgerald Remains a Buy on NewAmsterdam Pharma Company (NAMS)

Dennis Ding

Jefferies

$45

Buy

28.17%

Upside

Reiterated

06/11/25

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer's Opportunities

Debjit Chattopadhyay

Guggenheim

$35→$41

Buy

16.78%

Upside

Reiterated

03/03/25

NewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimNewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NewAmsterdam Pharma Company

1 Month

xxx

Success Rate

6/8 ratings generated profit

Average Return

+3.96%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +3.96% per trade.

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+25.39%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +25.39% per trade.

1 Year

George FarmerScotiabank

Success Rate

10/11 ratings generated profit

Average Return

+44.92%

reiterated a buy rating 5 months ago

Copying George Farmer's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +44.92% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+113.35%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +113.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NAMS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NAMS has received 11 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NAMS average Analyst price target in the past 3 months is 48.43.

Each month's total comprises the sum of three months' worth of ratings.

NAMS Financial Forecast

NAMS Earnings Forecast

Next quarter’s earnings estimate for NAMS is -$0.40 with a range of -$0.61 to -$0.08. The previous quarter’s EPS was -$0.61. NAMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NAMS has Performed in-line its overall industry.

NAMS Sales Forecast

Next quarter’s sales forecast for NAMS is $2.88M with a range of $0.00 to $14.00M. The previous quarter’s sales results were $348.00K. NAMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NAMS has Performed in-line its overall industry.

NAMS Stock Forecast FAQ

What is NAMS’s average 12-month price target, according to analysts?

Based on analyst ratings, NewAmsterdam Pharma Company’s 12-month average price target is 48.43.

What is NAMS’s upside potential, based on the analysts’ average price target?

NewAmsterdam Pharma Company has 37.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NAMS a Buy, Sell or Hold?

NewAmsterdam Pharma Company has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is NewAmsterdam Pharma Company’s price target?

The average price target for NewAmsterdam Pharma Company is 48.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $37.00. The average price target represents 37.94% Increase from the current price of $35.11.

What do analysts say about NewAmsterdam Pharma Company?

NewAmsterdam Pharma Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of NAMS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

NewAmsterdam Pharma Company (NAMS) Stock Forecast & Price Target

NAMS Analyst Ratings

NAMS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NewAmsterdam Pharma Company

NAMS Analyst Recommendation Trends

NAMS Financial Forecast

NAMS Earnings Forecast

NAMS Sales Forecast

NAMS Stock Forecast FAQ

Detailed List of Analyst Forecasts